Mylan launches first bioequivalent alternative to combination asthma therapy Seretide Evohaler
3M Drug Delivery Systems will fill, assemble and package Sirdupla at its manufacturing facility in Loughborough, UK
Mylan has launched the first bioequivalent alternative to GlaxoSmithKline’s Seretide Evohaler (salmeterol xinafoate/fluticasone propionate) under the brand name Sirdupla in the UK.1
Sirdupla is a pressurised metered-dose inhaler (pMDI) and is indicated to help treat or prevent symptoms of asthma in adults.2,3 The product is being manufactured by 3M Drug Delivery Systems, which will fill, assemble and package Sirdupla at its manufacturing facility in Loughborough, UK.
With 5.4 million people suffering from asthma in the UK, the condition costs the National Health Service (NHS) £1bn (US$1.53bn) annually.4
'Mylan is excited to be the first company to offer adult asthma patients in the UK the generic version of Seretide Evohaler, delivering on our mission to increase access to high quality medicine,' said Mylan President Rajiv Malik. 'Sirdupla represents a significant advance for the company that both strengthens our respiratory portfolio and pipeline and further demonstrates our ability to successfully execute on one of our key strategic growth drivers.'
'By partnering with Mylan, 3M has taken an important step forward in the generics space. This partnership combines 3M’s expertise in inhalation drug development and manufacturing with Mylan’s leadership position in the global generics market, including expertise in commercialising complex respiratory products,' said Cindy Kent, President and General Manager – 3M Drug Delivery Systems.
References
1. Data on file, Mylan.
2. Sirdupla 125/25mcg Summary of Product Characteristics. May 2015.
3. Sirdupla 250/25mcg Summary of Product Characteristics. May 2015.
4. Asthma UK. Asthma facts and FAQs. http://www.asthma.org.uk/asthma-facts-and-statistics Accessed on April 30, 2015.